Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) have been given a consensus recommendation of “Hold” by the twenty-one ratings firms that are currently covering the stock, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have assigned a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $124.11.

A number of research firms have recently commented on ZBH. Truist Financial boosted their price objective on Zimmer Biomet from $117.00 to $118.00 and gave the stock a “hold” rating in a research note on Wednesday, December 18th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a report on Wednesday. Royal Bank of Canada lifted their price objective on shares of Zimmer Biomet from $120.00 to $125.00 and gave the stock an “outperform” rating in a research note on Monday, November 4th. Oppenheimer decreased their price target on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 15th. Finally, Wells Fargo & Company raised their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 31st.

Zimmer Biomet Stock Down 0.5 %

Zimmer Biomet stock opened at $111.25 on Thursday. The company’s 50-day moving average price is $107.87 and its two-hundred day moving average price is $108.20. The stock has a market cap of $22.15 billion, a price-to-earnings ratio of 21.15, a PEG ratio of 1.88 and a beta of 1.02. Zimmer Biomet has a 52 week low of $100.67 and a 52 week high of $133.90. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, hitting the consensus estimate of $1.74. The firm had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm’s quarterly revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.65 earnings per share. On average, analysts expect that Zimmer Biomet will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be given a $0.24 dividend. The ex-dividend date is Monday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 0.86%. Zimmer Biomet’s payout ratio is 18.25%.

Institutional Trading of Zimmer Biomet

Several hedge funds and other institutional investors have recently modified their holdings of the company. Stonebridge Financial Group LLC purchased a new stake in shares of Zimmer Biomet during the 4th quarter worth about $25,000. Dunhill Financial LLC grew its position in Zimmer Biomet by 1,090.0% in the third quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after acquiring an additional 218 shares in the last quarter. Ashton Thomas Securities LLC acquired a new position in shares of Zimmer Biomet during the 3rd quarter worth $28,000. Bangor Savings Bank acquired a new stake in shares of Zimmer Biomet in the 3rd quarter valued at $31,000. Finally, Brooklyn Investment Group bought a new stake in Zimmer Biomet in the third quarter worth $35,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.